

**Correction to
Lancet Oncol 2016;
17: 747–56**

Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. *Lancet Oncol* 2016; **17**: 747–56—In Results, “median overall survival” should have been “Median time of death (after randomisation) in eleven patients who died from progressive disease”. This correction has been made to the online version as of May 29, 2019.

**Correction to
Lancet Oncol 2017;
18: 1061–75**

Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. *Lancet Oncol* 2017; **18**: 1061–75—In this Article, in figure 2A, the units on the y-axis should have been ng/mL. This correction has been made to the online version as of May 29, 2019.

**Correction to
Lancet Oncol 2018;
19: 1530–42**

Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. *Lancet Oncol* 2018; **19**: 1530–42—In figure 3, the data points for complete metabolic response and no complete metabolic response were incorrectly drawn in-house. They have been redrawn. This correction has been made to the online Article as of April 29, 2019.

**Correction to
Lancet Oncol 2019;
20: e262–73**

Ngiam KY, Khor IW. Big data and machine learning algorithms for health-care delivery. *Lancet Oncol* 2019; **20**: e262–73—Tables 1 and 2 in this Article have been corrected as of April 29, 2019.

**Correction to
Lancet Oncol 2019;
20: 297–310**

Cella D, Grünwald V, Escudier B, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. *Lancet Oncol* 2019; **20**: 297–310—In this Article, the list of study sites and investigators in the supplementary web appendix has been updated. This update has been made online as of May 29, 2019.

**Correction to
Lancet Oncol 2019;
20: 816–26**

Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. *Lancet Oncol* 2019; **20**: 816–26—The appendix of this Article has been updated as of May 10, 2019.

Published Online
April 29, 2019
[http://dx.doi.org/10.1016/S1470-2045\(19\)30280-3](http://dx.doi.org/10.1016/S1470-2045(19)30280-3)

Published Online
May 10, 2019
[http://dx.doi.org/10.1016/S1470-2045\(19\)30292-X](http://dx.doi.org/10.1016/S1470-2045(19)30292-X)

**Correction to
Lancet Oncol 2019;
20: 827–36**

Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. *Lancet Oncol* 2019; **20**: 827–36—The appendix of this Article has been updated as of May 10, 2019.

Published Online
May 10, 2019
[http://dx.doi.org/10.1016/S1470-2045\(19\)30293-1](http://dx.doi.org/10.1016/S1470-2045(19)30293-1)

**Correction to
Lancet Oncol 2019;
20: 849–61**

Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol* 2019; **20**: 849–61—In the list of IMblaze370 Investigators, the name “Van Cutsem E” has been corrected. This correction has been made to the online version as of May 29, 2019 and the printed Article is correct.